2022
DOI: 10.1080/10717544.2022.2152136
|View full text |Cite
|
Sign up to set email alerts
|

Immunomodulatory nano-preparations for rheumatoid arthritis

Abstract: Rheumatoid arthritis (RA) is a systemic autoimmune disease (AD) caused by the aberrant attack of the immune system on its own joint tissues. Genetic and environmental factors are the main reasons of immune system impairment and high incidence of RA. Although there are medications on the market that lessen disease activity, there is no known cure for RA, and patients are at risk in varying degrees of systemic immunosuppression. By transporting (encapsulating or surface binding) RA-related self-antigens, nucleic… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 14 publications
(4 citation statements)
references
References 117 publications
0
4
0
Order By: Relevance
“…A surge has recently been witnessed in nanomedicine development for combating RA, and this development is aimed at bypassing the defects of current treatments. [37][38][39] Polymeric micelles have become a highly promising biocompatible drug delivery platform. They have exhibited improved pharmacokinetic profiles in preclinical animal models and augmented the efficacy and superior safety of therapeutic drugs.…”
Section: Discussionmentioning
confidence: 99%
“…A surge has recently been witnessed in nanomedicine development for combating RA, and this development is aimed at bypassing the defects of current treatments. [37][38][39] Polymeric micelles have become a highly promising biocompatible drug delivery platform. They have exhibited improved pharmacokinetic profiles in preclinical animal models and augmented the efficacy and superior safety of therapeutic drugs.…”
Section: Discussionmentioning
confidence: 99%
“…have the advantages of reducing the difficulty of administration, improving patient compliance, and reducing the burden on patients. Through the oral route nanoparticles can reach gut-associated lymphoid tissues and encounter DCs in these tissues to induce immune tolerance ( Chen et al, 2018 ; Li et al, 2023 ). It should also be noted that after oral administration of nanoparticles, the amount of drug entering the circulation tend to be reduced due to first pass elimination, and the high acid environment in the stomach may result in the degradation of nanoparticles ( Abeer et al, 2020 ; Horvath and Basler, 2023 ).…”
Section: Nanodrug Delivery Systems Targeting Dcs To Induce Immune Tol...mentioning
confidence: 99%
“…Frontiers in Bioengineering and Biotechnology frontiersin.org (Chen et al, 2018;Li et al, 2023). It should also be noted that after oral administration of nanoparticles, the amount of drug entering the circulation tend to be reduced due to first pass elimination, and the high acid environment in the stomach may result in the degradation of nanoparticles (Abeer et al, 2020;Horvath and Basler, 2023).…”
Section: Administration Routes Of DC Targeting Nanoparticlesmentioning
confidence: 99%
“…RA seriously affects the patients' quality of life and life expectancy. [40] RA may cause a series of systemic health problems, including cardiovascular, pulmonary, psychological, skin, and bone diseases. [41] The resultant abnormal synovial tissue expansion is accompanied by neovascularization, intimal hyperplasia, increased inflammatory cytokines, and autoantibodies such as anticitrullinated protein antibodies, and rheumatoid factor (RF).…”
Section: Rheumatoid Arthritismentioning
confidence: 99%